All data are based on the daily closing price as of October 8, 2025
s

SanBio

4592.TSE
23.17 USD
0.29
+1.27%

Overview

Last close
23.17 usd
Market cap
1.67B usd
52 week high
25.59 usd
52 week low
2.63 usd
Target price
11.64 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
3458.1885
Price/Book Value
185.6111
Enterprise Value
1.56B usd
EV/Revenue
3405.5195
EV/EBITDA
-9.0194

Key financials

Revenue TTM
150553.12 usd
Gross Profit TTM
2.93M usd
EBITDA TTM
-25.04M usd
Earnings per Share
-0.33 usd
Dividend
N/A usd
Total assets
21.50M usd
Net debt
-9.23M usd

About

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
  • Symbol
    4592.TSE
  • Exchange
    TSE
  • Isin
    JP3336750009
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
  • Headquarter
    Tokyo
  • Web site
    https://www.sanbio.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top